China Hepatitis B Treatment Market
完整報告名稱與涵蓋範圍
China Hepatitis B Treatment Market Competitive Landscape and Forecast till 2035
報告摘要
The China Hepatitis B Treatment Market Competitive Landscape and Forecast till 2035 report evaluates market concentration, company shares, and competitive strategies of domestic and multinational pharmaceutical firms operating in China through 2035.
Key strategies include volume-based procurement (VBP) participation, strategic drug licensing, and innovative combination therapy development. Market expansion is driven by high disease prevalence and expanded national reimbursement lists (NRDL). Restraints include steep price cuts from government tender policies, forcing players to focus on long-acting antivirals and novel functional cure pipelines.
授權報價
| Single User Price | $750 USD |
| Multi User Licence (up to 10 users) | $1,000 USD |
| Enterprisewide Price (Global Site License) | $1,250 USD |
目錄 Table of Contents
TABLE OF CONTENT
1.1 Introduction 12
1.2 market share analysis, 2025 12
1.3 competitor dashboard 13
1.4 Comparative analysis: Key players financial 14
1.5 Key Developments 14
2 COMPANY PROFILES 15
2.1 Gilead Sciences, Inc 15
2.1.1 COMPANY OVERVIEW 15
2.1.2 FINANCIAL OVERVIEW 16
2.1.3 PRODUCTS OFFERED 16
2.1.4 KEY DEVELOPMENTS 17
2.1.5 SWOT ANALYSIS 17
2.1.6 KEY STRATEGY 18
2.2 Bristol Myers Squibb 19
2.2.1 COMPANY OVERVIEW 19
2.2.2 FINANCIAL OVERVIEW 20
2.2.3 PRODUCTS OFFERED 20
2.2.4 KEY DEVELOPMENTS 21
2.2.5 SWOT ANALYSIS 21
2.2.6 KEY STRATEGY 22
2.3 Novartis 23
2.3.1 COMPANY OVERVIEW 23
2.3.2 FINANCIAL OVERVIEW 24
2.3.3 PRODUCTS OFFERED 24
2.3.4 KEY DEVELOPMENTS 25
2.3.5 SWOT ANALYSIS 25
2.3.6 KEY STRATEGY 26
2.4 GlaxoSmithKline (GSK plc) 27
2.4.1 COMPANY OVERVIEW 27
2.4.2 FINANCIAL OVERVIEW 28
2.4.3 PRODUCTS OFFERED 29
2.4.4 KEY DEVELOPMENTS 29
2.4.5 SWOT ANALYSIS 30
2.4.6 KEY STRATEGY 31
2.5 Amoy top Biotech Co., Ltd 32
2.5.1 COMPANY OVERVIEW 32
2.5.2 FINANCIAL OVERVIEW 33
2.5.3 PRODUCTS OFFERED 33
2.5.4 KEY DEVELOPMENTS 34
2.5.5 SWOT ANALYSIS 34
2.5.6 KEY STRATEGY 35
2.6 Tianqing Pharmaceutical Group Co., Ltd 36
2.6.1 COMPANY OVERVIEW 36
2.6.2 FINANCIAL OVERVIEW 36
2.6.3 PRODUCTS OFFERED 37
2.6.4 KEY DEVELOPMENTS 37
2.6.5 SWOT ANALYSIS 38
2.6.6 KEY STRATEGY 39
2.7 Sino Biopharmaceutical Limited 40
2.7.1 COMPANY OVERVIEW 40
2.7.2 FINANCIAL OVERVIEW 41
2.7.3 PRODUCTS OFFERED 42
2.7.4 KEY DEVELOPMENTS 42
2.7.5 SWOT ANALYSIS 43
2.7.6 KEY STRATEGY 44
2.8 Jiangsu Hansoh Pharmaceutical Co., Ltd 45
2.8.1 COMPANY OVERVIEW 45
2.8.2 FINANCIAL OVERVIEW 46
2.8.3 PRODUCTS OFFERED 46
2.8.4 KEY DEVELOPMENTS 47
2.8.5 SWOT ANALYSIS 47
2.8.6 KEY STRATEGY 48
2.9 AusperBio 49
2.9.1 COMPANY OVERVIEW 49
2.9.2 FINANCIAL OVERVIEW 49
2.9.3 PRODUCTS OFFERED 50
2.9.4 KEY DEVELOPMENTS 50
2.9.5 SWOT ANALYSIS 51
2.9.6 KEY STRATEGY 52
2.10 Ascletis Bioscience Co., Ltd 53
2.10.1 COMPANY OVERVIEW 53
2.10.2 FINANCIAL OVERVIEW 53
2.10.3 PRODUCTS OFFERED 54
2.10.4 KEY DEVELOPMENTS 54
2.10.5 SWOT ANALYSIS 55
2.10.6 KEY STRATEGY 56
3 DATA CITATIONS 57
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL 14
TABLE 2 KEY DEVELOPMENTS 14
TABLE 3 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 17
TABLE 4 GILEAD SCIENCES, INC.: KEY DEVELOPMENTS 18
TABLE 5 BRISTOL MYERS SQUIBB: PRODUCTS OFFERED 22
TABLE 6 BRISTOL MYERS SQUIBB: KEY DEVELOPMENTS 24
TABLE 7 NOVARTIS: PRODUCTS OFFERED 27
TABLE 8 GLAXOSMITHKLINE (GSK PLC): PRODUCTS OFFERED 33
TABLE 9 GSK: KEY DEVELOPMENTS 33
TABLE 10 AMOYTOP BIOTECH CO., LTD.: PRODUCTS OFFERED 37
TABLE 11 TIANQING PHARMACEUTICAL GROUP CO., LTD: PRODUCTS OFFERED 42
TABLE 12 SINO BIOPHARMACEUTICAL LIMITED CO., LTD.: PRODUCTS OFFERED 47
TABLE 13 JIANGSU HANSOH PHARMACEUTICAL CO., LTD. CO., LTD.: PRODUCTS OFFERED 52
TABLE 14 AUSPERBIO CO., LTD.: PRODUCTS OFFERED 56
TABLE 15 ASCLETIS BIOSCIENCE CO., LTD. CO., LTD.: PRODUCTS OFFERED 60
LIST OF FIGURES
FIGURE 1 CHINA HEPATITIS B TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 12
FIGURE 2 COMPETITOR DASHBOARD: CHINA HEPATITIS B TREATMENT 13
FIGURE 3 GILEAD SCIENCES, INC.: FINANCIAL OVERVIEW 17
FIGURE 4 GILEAD SCIENCES, INC.: SWOT ANALYSIS 18
FIGURE 5 BRISTOL MYERS SQUIBB: FINANCIAL OVERVIEW 22
FIGURE 6 BRISTOL MYERS SQUIBB: SWOT ANALYSIS 24
FIGURE 7 NOVARTIS: FINANCIAL OVERVIEW 27
FIGURE 8 NOVARTIS: SWOT ANALYSIS 29
FIGURE 9 GLAXOSMITHKLINE (GSK PLC): FINANCIAL OVERVIEW 32
FIGURE 10 GLAXOSMITHKLINE (GSK PLC): SWOT ANALYSIS 34
FIGURE 11 AMOYTOP BIOTECH CO., LTD.: FINANCIAL OVERVIEW 37
FIGURE 12 AMOYTOP BIOTECH CO., LTD.: SWOT ANALYSIS 39
FIGURE 13 TIANQING PHARMACEUTICAL GROUP CO., LTD: SWOT ANALYSIS 43
FIGURE 14 SINO BIOPHARMACEUTICAL LIMITED CO., LTD.: FINANCIAL OVERVIEW 46
FIGURE 15 SINO BIOPHARMACEUTICAL LIMITED CO., LTD.: SWOT ANALYSIS 49
FIGURE 16 JIANGSU HANSOH PHARMACEUTICAL CO., LTD. CO., LTD.: FINANCIAL OVERVIEW 52
FIGURE 17 JIANGSU HANSOH PHARMACEUTICAL CO., LTD. CO., LTD.: SWOT ANALYSIS 53
FIGURE 18 AUSPERBIO CO., LTD.: SWOT ANALYSIS 57
FIGURE 19 ASCLETIS BIOSCIENCE CO., LTD. CO., LTD.: SWOT ANALYSIS 61
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們